The deal is the consequence of a divestiture process mandated by the Federal Trade Commission (FTC) in association with Amneal Pharmaceutical’s proposed business combination with Impax Laboratories. Under
The CGRP receptor antagonist, which was orally administered, was assessed in both 25mg and 50mg doses in comparison to placebo for the acute treatment of migraine in 1,686
The breakthrough designation for the drug is especially for HSCT-TMA patients with persistent TMA in spite of modification of immunosuppressive therapy. OMS721 is a human monoclonal antibody that
The European Union patent and trademark office (EPO) has approved the EU patent application no. 08717866.1 (anti-androgen peptides and uses thereof in cancer therapy), which covered the firm’s
Risankizumab is a humanized monoclonal antibody, designed to selectively inhibit IL-23 by binding to its p19 subunit. IL-23 is an important cytokine involved in inflammatory processes, and is
As per the revised proposal, Takeda offers to pay nearly £49 per each share of Shire in the form of £21.75 in cash and £27.26 in new Takeda
The Phase 2b Pronto study did not meet its primary or secondary endpoints. A phase 3 Vital Amyloidosis study is also being discontinued based on futility analysis. AL amyloidosis is a
Pfizer said that the additional requested information asked in the Complete Response Letter (CRL) sent by the US regulator is not related to safety or clinical data submitted
The partnership will use Biogen’s expertise in neuroscience research and drug development and Ionis’ capabilities in RNA targeted therapies to develop a range of investigational therapies. As per
The German healthcare firm alleged that its independent investigation found material breaches of US Food and Drug Administration (FDA) integrity requirements relating to Akorn’s product development activities. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.